Surface Oncology Inc (NASDAQ:SURF)
| 3.64 Delayed Data As of Jan 26 |  -0.20 / -5.21%Today’s Change | 3.52 Today|||52-Week Range 12.98 | -23.85% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $171.6M |
Company Description
Surface Oncology, Inc. operates as a clinical-stage immuno-oncology company. It focuses on biological pathways critical to the immunosuppressive tumor microenvironment and the development of next-generation cancer therapies. The firm's pipeline includes wholly-owned lead programs targeting CD39 (SRF617) and IL-27 (SRF388), as well as a preclinical program focused on depleting tumor regulatory T cells via targeting CCR8 (SRF114). Its pipeline also include licensed product programs, such as a collaboration with Novartis targeting CD73 (NZV930; Phase 1) and a collaboration with GlaxoSmithKline targeting PVRIG (SRF813; preclinical). The company was founded by David S. Grayzel in 2014 and is headquartered in Cambridge, MA.
Contact Information
Surface Oncology, Inc. 50 Hampshire Street Cambridge Massachusetts 02139 |
Employees
Shareholders
| Individual stakeholders | 35.82% |
| Mutual fund holders | 29.76% |
| Other institutional | 13.80% |
Top Executives
| Robert W. Ross | President, Chief Executive Officer & Director |
| Jessica Fees | Chief Financial Officer |
| Vito J. Palombella | Chief Scientific Officer |
| Alison M. O'Neill | Chief Medical Officer |
| Shannon Rourke Devens | Senior Vice President-Development Operation |
